Sensible wins $25,000 HLTH pitch prize with a menstrual-blood wearable

The North Carolina startup described a consumer launch followed by clinical development as judges tested founders on evidence, payment and how their products would reach patients.

Author
HDM Staff
Save
Share
Judges onstage beside a screen announcing the HLTH USA 2026 Startup Competition winner.
Judges applaud during the winner announcement at the HLTH USA 2026 Startup Competition. Photo credit: HLTH USA 2026

    Sensible won the $25,000 HLTH USA startup pitch prize Wednesday after presenting a wearable designed to collect and analyze menstrual blood overnight. Founder and CEO Nandini Kanthi described an initial consumer product and a longer-term effort to turn those measurements into information clinicians could use in assessing conditions such as endometriosis.

    The company is developing a disposable attachment to a menstrual pad, with collection and sensing components intended to feed information to an application. “Women’s health has a measurement problem,” Kanthi said. She told judges the company plans to enter through consumer use while pursuing the evidence and regulatory work needed for clinical applications, adding that “our focus is the clinical application.”

    Kanthi described a proposed $19 monthly subscription and conversations with diagnostic companies about pilots. She said Sensible was studying a biomarker with the University of North Carolina School of Medicine, while giving no completed clinical validation results for the proposed wearable during the pitch. The UNC Gillings school has separately described the pad-attachable patch and the student-led company’s earlier participation in the ACC InVenture Prize.

    The award closed the Main Stage competition in Las Vegas, where founders took questions about who would pay, what evidence they had and how their companies would get into clinical workflows. Cooley partner Matthew Schwee emceed the event. The judges were Cooley corporate partner Colleen Badgley, Aegis Ventures co-founder and managing partner John Beadle and LifeX Ventures managing partner Amol Sarva.

    The organizer announced 12 finalists and a prize package including two passes to HLTH USA 2027 and a featured interview. Across those pitches, founders described businesses at different stages of development, from plans for validation studies to operating care services with revenue, making the questions about evidence and distribution particularly consequential.

    Measurements that need a route into care

    Sensible’s win put a spotlight on a problem also raised by Alexandra Oti, co-founder of Unravel Health. Oti described a device for measuring hormone patterns over time and said, “It measures four hormones at once in saliva.” She told judges Unravel intends to reach customers through clinics, health applications and other distribution partners, with consumers paying and the partner sharing in revenue.

    “We are building for integration,” Oti said. She described a $400 hardware and three-month testing package and said the company had recently closed a $3 million pre-seed round. The company’s website identifies a team working on at-home hormone monitoring, but the pitch’s claims about sensitivity, partner reach and eventual clinical uses were the company’s account of its work.

    Terri Mock, introduced on the agenda as Theresa Mock, presented Zephyr Apnea Technologies’ proposed wearable therapy for obstructive sleep apnea. She described a surface-stimulation patch designed around “no mask, no hoses, no surgery, just sleep.” When asked about payment, she said the company expected to begin with cash pay and seek reimbursement codes, adding, “We will need to apply for them.”

    Mock said the company’s available results came from preliminary home-use testing and that an institutional-review-board-approved pilot was a next funding milestone. That puts the planned study and prescription pathway ahead of any claim that the patch can replace established therapy broadly. She said Zephyr would initially target people prescribed CPAP who were not using it.

    Sam Budoff, founder of Parley Neurotech, described an approach to difficulty hearing in noise that pairs a drug with sound-based stimulation. “It is a combination therapy,” he said, explaining that the two components were intended to work together. He emphasized clinical development and said “it deserves to go through the FDA path,” while discussing the challenge of persuading patients and clinicians that the problem can be treated.

    Parley’s leadership page identifies Samuel Budoff as CEO and co-founder and lists its clinical-trial work. The pitch offered a development and investment case, with no new randomized trial results presented in the retained remarks. Its eventual adoption will depend on evidence for the combined intervention and the indications regulators authorize.

    Care companies face questions about delivery

    Kevin Cyr, founder of Coralum Health, described a Parkinson’s service using patient and caregiver check-ins, wearable information and an extended clinical team. He said “symptoms can change every hour,” while care often responds far less frequently. Asked how his company would differ from symptom-tracking applications, Cyr said, “We actually unite our platform with real care.”

    Cyr described physician services and possible fee-for-service and value-based payment routes. He also said caregiver participation was central to the product’s design, including a dedicated way for a caregiver to contribute information under their own identity. Coralum’s patient information likewise describes check-ins designed for people with tremor and support for authorized family participation.

    Lucas Johnston, co-founder and CEO of Headquarters, presented a concussion-care service working through schools and athletic trainers. “Our partner organizations refer patients to us,” he said, describing a pathway from a school’s baseline testing and sideline evaluation to specialist assessment. Johnston reported more than 100 schools under contract and more than 300 patients treated over the preceding year.

    Johnston said “we own the full stack,” including clinicians and the company’s technology infrastructure. Judges asked why families would use its service instead of general telehealth and how the company differentiated its approach. His figures for access time, outcomes and revenue were company-reported, and the presentation did not provide a controlled comparison that would establish a treatment effect.

    ARSS technical founder Braden Barfuss described an automated repositioning sheet intended to help nursing staff turn patients at risk of pressure injuries. He called it “built by nursing staff for nursing staff” and described a reusable pump connected to disposable sheets with inflatable components. In explaining the patient experience, he described “a very slow and steady turn” on a programmable schedule.

    Barfuss said skilled nursing facilities were the initial market, followed by potential hospital and home-health uses. The University of Utah previously identified the automated repositioning project as its Bench to Bedside competition winner. The HLTH pitch focused on equipment and recurring sheet purchases, with no new controlled pressure-injury study reported in the remarks.

    Evidence and infrastructure behind the product

    Nabil Hafez, CEO of Genomate Health, described “a computational reasoning engine” for ranking possible cancer treatments using a patient’s molecular information. Asked about its clinical business, he said, “We offer a comprehensive precision medicine clinic.” He explained that the company pairs its technology with molecular specialists and oncologists, while also exploring drug-repurposing partnerships.

    Hafez presented company-reported treatment and survival comparisons and described plans to expand through second-opinion services and clinic partnerships. The pitch did not provide the study methods needed to judge those comparisons independently. Genomate’s conference announcement describes its work connecting molecular evidence with biological mechanisms to investigate treatment options and drug-development opportunities.

    Frederick Johnson, founder and CEO of Digital Therapeutix, described software for matching bacterial pathogens to bacteriophages and designing candidate phages when a match is unavailable. “We have a matching algorithm,” he said. His statement that “we can actually create a biologic” referred to the company’s candidate-generation approach, which he said it was working to validate with the University of Arkansas.

    Johnson said funding would support validation, publications and partnerships, with a possible researcher subscription service. Those are early development steps, and his presentation supplied no clinical evidence of a treatment generated by the platform curing an infection. The distinction between a computational candidate and a validated therapeutic is central to evaluating that business.

    Rishabh Goel, co-founder and CEO of Bond Health, described using AI to identify, contact and enroll patients for clinical trials. “What you want to see is an enrolled patient,” he said, explaining why the company aims to cover several steps in recruitment. He said “we start with the sites,” using work with trial locations to build evidence before seeking larger pharmaceutical contracts.

    Goel reported company results for enrollment and conversion from pilots to service agreements. He said Bond charges for screening and takes a share of patient-related milestone payments, which ties its economics to recruitment activity. The presentation gave no independently evaluated comparison across trials with different enrollment criteria, populations or recruitment budgets.

    Dana Allison, CEO of Trova Health, described the complexity digital health companies face when expanding “country by country.” She presented cloud infrastructure, a care-delivery platform and a provider network as the company’s response. For the network, Allison said, “We vet, we credential, we manage, we pay directly,” while explaining that clients can also bring their own providers onto the platform.

    Allison described fees that can vary by service and customer, including platform and care-delivery charges. Judges pressed her on the remaining barriers to cross-border expansion and the business’s competitive position. Her answer acknowledged that new services bring additional complexity, an operational limit that remains even when a company can supply the technology and provider network.

    The award gave Sensible money and visibility as it works toward its proposed consumer launch and clinical ambitions. Across the competition, founders still had to show how a measurement, model or piece of equipment becomes a product someone can validate, pay for and use. The judges’ questions made those next steps part of the public pitch.